CSNK1A1 and osteosarcoma: The phosphorylation of CBX4 at T437 by CK1α facilitates its ubiquitination and degradation by CHIP, and PP as a selective activator of CK1α may benefit osteosarcoma patients with high expression levels of CBX4.